Skip to content

Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage

Robot-Assisted Laparoscopic Radio Frequency Ablation Assisted Enucleation of Renal Cell Carcinoma With T1a Stage : Clinical Outcomes of a Randomised Controlled Trial

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02924597
Enrollment
100
Registered
2016-10-05
Start date
2016-01-31
Completion date
2018-08-31
Last updated
2016-10-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Renal Cell Carcinoma

Brief summary

To evaluate the feasibility and efficiency of zero ischemia robot-assisted laparoscopic radio frequency ablation assisted enucleation of T1a renal cell carcinoma in comparison with robot-assisted laparoscopic partial nephrectomy without hilar clamping.

Interventions

PROCEDUREzero ischemia robot-assisted laparoscopic RFA assisted TE
PROCEDUREzero ischemia robot-assisted laparoscopic partial nephrectomy

Sponsors

RenJi Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
15 Years to 80 Years
Healthy volunteers
No

Inclusion criteria

* patients with sporadic, unilateral, newly diagnosed T1a presumed renal cell carcinoma * patients scheduled for robot-assisted laparoscopic nephron sparing surgery * patients with normal contralateral renal function (differential renal function of \>40% as determined by radionuclide scintigraphy) * patients agreeable to participate in this long-term follow-up study

Exclusion criteria

* patients' aged \>80 years * patients with other renal diseases,(including kidney stone, glomerular nephritis, etc.) which might affect the renal function of the operative kidney * patients not able to tolerate the robot-assisted laparoscopic procedure * patients with previous renal surgery or history of any inflammatory conditions of the operative kidney * patients with the renal tumor involving urinary collecting system

Design outcomes

Primary

MeasureTime frameDescription
The absolute change in glomerular filtration rate (GFR) of the affected kidneybaseline and 12 months12 months minus baseline
The changes of estimated GFR (eGFR)baseline and 12 months12 months minus baseline

Secondary

MeasureTime frame
surgical marginpostoperative,up to 2 weeks after surgery
postoperative complicationspostoperative,up to 30 days
progression-free survival12 months
estimated blood lossduring surgery
operative timeDuring surgery
Hospital stay timeThe time from the surgery day to patient discharge, up to 2 weeks
changes in GFR of total kidneys by renal scintigraphyby of 6 monthbaseline and 6 months
local recurrence12 months
changes in GFR of total kidneys by renal scintigraphybybaseline and 12 months

Countries

China

Contacts

Primary ContactJin Zhang, PhD.
rjxuyunze@163.com+8618801967501
Backup ContactYiran Huang, MD.
huangyrrenji@163.com+8613501835219

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026